Slingerland Ann E, Schwabkey Zaker, Wiesnoski Diana H, Jenq Robert R
Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Front Immunol. 2017 Apr 12;8:400. doi: 10.3389/fimmu.2017.00400. eCollection 2017.
Clinical evidence is accumulating for a role of the microbiome in contributing to or modulating severity of inflammatory diseases. These studies can be organized by various organ systems involved, as well as type of study approach utilized, whether investigators compared the microbiome of cases versus controls, followed patients longitudinally, or intervened with antibiotics, prebiotics, or bacterial introduction. In this review, we summarize the clinical evidence supporting the microbiome as an important mechanism in the onset and maintenance of inflammation.
越来越多的临床证据表明，微生物群在促成或调节炎症性疾病的严重程度方面发挥作用。这些研究可以根据所涉及的各种器官系统以及所采用的研究方法类型进行整理，无论研究人员是比较病例与对照的微生物群、对患者进行纵向随访，还是使用抗生素、益生元或引入细菌进行干预。在本综述中，我们总结了支持微生物群作为炎症发生和维持的重要机制的临床证据。
